Section Arrow
SPRY.NASDAQ
- ARS Pharmaceuticals
Quotes are at least 15-min delayed:2026/11/04 13:17 EST
Regular Hours
Last
 3.05
0 (0.00%)
Day High 
3.225 
Prev. Close
3.05 
1-M High
4.635 
Volume 
1.31M 
Bid
3.05
Ask
3.06
Day Low
2.995 
Open
3.14 
1-M Low
2.91 
Market Cap 
303.31M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.7 
20-SMA 3.94 
50-SMA 4.48 
52-W High 13.15 
52-W Low 2.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.18/-0.44
Enterprise Value
399.69M
Balance Sheet
Book Value Per Share
0.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
84.28M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.249+0.5351+74.95%0.2PE
KPTIKaryopharm Therapeutics Inc.0.09+0.0017+1.93%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.73+0.07+4.22%-- 
RXRXRecursion Pharmaceuticals3.89+0.21+5.71%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.